1.3.98.1	analysis	protocol to measure enzyme kinetic parameters based on isothermal titration calorimetry. Presence of dimethyl sulfoxide at 10%, v/v and Triton X-100 at 0.5%, v/v seems to facilitate the substrate binding process with a small decrease in KM value	710846	
1.3.98.1	medicine	despite their genetic variations, kinetic properties of the three DHODs are conserved, these findings facilitate further exploitation of Trypanosoma cruzi DHOD inhibitors, as chemotherapeutic agents against Chagas' disease	676289	
1.3.98.1	medicine	enzyme is inhibited by 59% and 58% by methanol extracts of the brown algae Fucus evanescens and Pelvetia babingtonii, resp., the extracts decrease significantly the infection rate of HeLa host cells and the average parasite number per infected cell	656891	
1.3.98.1	medicine	in patients with rheumatoid arthritis treated with leflunomide, the frequency of remission is increased in patients carrying the C allele of single nucleotide polymorphism 19C>A compared with patients carrying the A allele	700606	
1.3.98.1	medicine	integration of a single copy of the yeast fumarate-dependent dihydroorotate dehydrogenase gene yDHODH into the genomes of strains D10attB, 3D7attB, Dd2attB, and HB3attB of Plasmodium falciparum. The yeast gene is equally expressed in all of the transgenic lines. All four yeast dihydroorotate dehydrogenase transgenic lines show strong resistance to atovaquone in standard short-term growth inhibition assays. During longer term growth with atovaquone, D10attB-yDHODH and 3D7attB-yDHODH parasites remain fully resistant, but Dd2attB-yDHODH and HB3attB-yDHODH parasites lose their tolerance to the drug after 3 to 4 days of exposure. No differences are found in growth responses among all of these strains to the Plasmodium-specific DHODH inhibitor DSM1 in either short- or long-term exposures. The ubiquinone analog decylubiquinone substantially reverses the atovaquone inhibition of Dd2attB-yDHODH and HB3attByDHODH transgenic parasites during extended growth	724890	
1.3.98.1	medicine	use of yeast enzyme as a positive selectable marker for transfections of Plasmodium falciparum, including its use in gene disruption strategies. A transfection vector designed for gene disruption, containing the yeast DHODH gene as the positive selection marker in combination with a previously described fused yeast cytosine deaminase-uracil phosphoribosyl transferase gene as a negative selection marker, yields positively selected parasites containing the plasmid after transfection of the Plasmodium falciparum D10 strain followed by selection with atovaquone. Yeast DHODH transgenic parasites can be selected in strains D10 and Dd2 by Plasmodium DHODH-specific triazolopyrimidine-based inhibitors	725915	
1.3.98.1	additional information	an ancient common ancestor of Euglenozoa had a mitochondrial DHOD whose descendant exists in Euglena gracilis	675478	
1.3.98.1	additional information	Bodo saliens has an ACT/DHOD gene fusion encoding aspartate carbamoyltransferase, the second enzyme of the de novo pyrimidine pathway, and DHOD	675478	
1.3.98.1	additional information	significant heterogeneity in the catalytic behaviors of individual dimer molecules, very similar reaction rates in both the reductive and oxidative half-reactions for different DHODA dimers, single-molecule data provide strong evidence for half-sites reactivity, in which only one subunit reacts at a time	676859	
1.3.98.1	additional information	species-specific preferential inhibitor binding, different binding mode for the same inhibitor in the two catalytically identical enzymes human DHODH and Plasmodium DHODH	671050